摘要
目的探讨骨髓增生异常综合征(MDS)患者骨髓细胞中P16基因表达异常态势,为寻找MDS患者分子诊断标记提供实验依据。方法采用荧光实时定量聚合酶联反应检测44例初诊和18例治疗后MDS患者骨髓单个核细胞中P16基因mRNA表达水平,并与15例非MDS贫血患者相比较。磁珠分选8例初诊MDS患者CD34+细胞,并用流式细胞仪检测细胞纯度。检测MDS患者骨髓单个核细胞及CD34+细胞中P16表达水平。结果在单个核细胞中,初诊MDS组与治疗后MDS组P16基因表达水平均显著高于非MDS贫血组,差异均有高度统计学意义(P<0.001)。流式细胞仪检测CD34+细胞纯度为96.7%,在CD34+细胞中,初诊MDS组P16基因表达水平显著高于非MDS贫血组,差异有统计学意义(P<0.05)。结论MDS患者P16表达异常可发生在CD34+细胞,也可发生在分化后较成熟的单个核细胞。P16基因可作为MDS鉴别诊断的分子标志物之一,其在MDS患者细胞凋亡中可能发挥作用。
Objective To study the mRNA expression of P16 gene in myelodysplastic syndromes（MDS） patients.Methods P16 mRNA expression level was detected by real time quantitative reverse transcriptase polymerase chain reaction.The expression level of P16 in 44 newly diagnosed MDS pa-tients and 18 treated patients was compared with that in 15 non-MDS anemia patients by using SPSS15 software.CD34＋ cells from 8 patients with MDS were selected by binding to immunomagnetic beads and subjected to P16 expression determination.Purity check on CD34＋ cells was analyzed by flow cytometry.The P16 expression level of bone marrow mononuclear cells and CD34＋ cells in MDS patient was de-tected.Results The mRNA expression level of P16 in bone marrow mononuclear cells was significant-ly higher than that in the non-MDS anemia group（P〈0.001）.And the P16 expression of treated MDS pa-tients was also higher than that in the non-MDS anemia group（P〈0.001）.The purity of CD34＋ cells was 96.7%.And the CD34＋ cell P16 expression in the MDS patients was higher than that in the non-MDS anemia group（P〈0.05）.Conclusion The abnormal expression of P16 in MDS may happen in either CD34＋ cells or mononuclear cells.P16 can serve as one of the biomarkers for MDS differential diagnosis and its high expression may be involved with being prone to apoptosis in MDS.
出处
《苏州大学学报（医学版）》
CAS
北大核心
2008年第6期956-958,共3页
Suzhou University Journal of Medical Science
基金
国家自然科学基金资助项目(30470733)
江苏省自然科学基金资助项目(BK2004040)
